Rociletinib

1374640-70-6

C27H28F3N7O3

DMSO : >= 43 mg/mL (77.40 mM)

JAK/STAT Signaling; Protein Tyrosine Kinase/RTK

Rociletinib (CO-1686) is an orally delivered kinase inhibitor that specifically targets the mutant forms of EGFR including T790M, and the K_i values for EGFRL858R/T790M and EGFRWT are 21.5 nM and 303.3 nM, respectively. IC50 & Target: Ki: 21.5 nM (EGFRL858R/T790M), 303.3 nM (EGFR) In Vitro: Rociletinib (CO-1686) (0.1 uM) inhibits EGFR potently and irreversibly, and inhibits more than 50% of 23 targets. Rociletinib potently and selectively inhibits growth of NSCLC cells expressing mutant EGFR and induces apoptosis. Rociletinib resistant NSCLC cell lines are sensitive to AKT inhibition^[1]. In Vivo: Rociletinib (CO-1686) (100 mg/kg/day, p.o.) demonstrates anti-tumor activity in NSCLC EGFR mutant xenograft models. Rociletinib (CO-1686) (50 mg/kg bid, p.o.) demonstrates anti-tumor activity in human EGFR-L858R and EGFR-L858R-T790M expressing transgenic mice^[1].